SNDX

Syndax Pharmaceuticals Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website yndax.com
Employees(FY) 107
ISIN US87164F1057

Performance

-2.9%

-17.06%

-29.79%

-31.37%

-39.47%

YTD

-33.6%

Profile

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of SNDX 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance, and the Technical Score of 33 reinforces the bearish outlook. This combination implies that while there may be some oscillatory movements, the prevailing tre...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SNDX

Stock Rank

Recent News & Updates

2024-12-09 07:30
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial(PR Newswire)
2024-12-08 18:30
Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial(Prnewswire)
2024-12-07 18:15
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting(PR Newswire)
2024-12-07 05:15
Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting(Prnewswire)
2024-12-04 13:32
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?(Insider Monkey)
2024-12-03 16:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(PR Newswire)
2024-12-03 03:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Prnewswire)
2024-11-27 07:00
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference(PR Newswire)
2024-11-26 18:00
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference(Prnewswire)
2024-11-18 07:12
Syndax secures FDA OK for new kind of leukemia drug(BioPharma Dive)
2024-11-18 06:39
FDA approves Syndax’s Revuforj to treat leukaemia(Pharmaceutical Technology)
2024-11-15 17:29
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation(PR Newswire)
2024-11-15 04:29
Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation(Prnewswire)
2024-11-14 14:16
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data(Zacks)
2024-11-13 19:00
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon(Prnewswire)
2024-11-13 13:06
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint(Pharmaceutical Technology)
2024-11-13 07:21
Syndax’s revumenib meets primary results in AML trial(TipRanks)
2024-11-12 13:07
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer(Benzinga)
2024-11-12 07:00
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib(PR Newswire)
2024-11-11 18:00
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib(Prnewswire)
2024-11-08 05:44
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results(Simply Wall St.)
2024-11-07 00:32
Q3 2024 Royalty Pharma PLC Earnings Call(Thomson Reuters StreetEvents)
2024-11-06 12:16
Q3 2024 Syndax Pharmaceuticals Inc Earnings Call(Thomson Reuters StreetEvents)
2024-11-06 05:00
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale(BioPharma Dive)
2024-11-06 02:23
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...(GuruFocus.com)
2024-11-05 17:10
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-05 16:09
Syndax: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-05 16:01
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update(PR Newswire)
2024-11-05 09:01
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024(PR Newswire)
2024-11-05 09:00
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting(PR Newswire)

Page 1 of 9

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.